Uptravi

Chemical Nameselexipag
Dosage FormTablet (oral; 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg)
Drug ClassReceptor agonists
SystemCardiovascular
CompanyActelion Pharms Ltd
Approval Year2015

Indication

  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Uptravi (selexipag) Prescribing Information2019Actelion Pharmaceuticals US, Inc., South San Francisco, CA
Document TitleYearSource
Clinical review report: Slexipag (Uptravi).2017CADTH